Prescription drug Enalapril Maleate recalled for manufacturing deviations
Golden State Medical Supply Inc. is recalling Enalapril Maleate 2.5 mg tablets due to Current Good Manufacturing Practice (CGMP) deviations. Approximately 1,471 bottles were distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with voluntary firm initiation and no reported illnesses or injuries. CGMP deviations represent manufacturing quality control issues without confirmed patient harm.
Plain-English summary
Enalapril Maleate Tablets, USP 2.5 mg (NDC 60429-183-90) are being recalled by Golden State Medical Supply Inc. The product was manufactured by Taro Pharmaceutical Industries, Ltd., and packaged by Golden State Medical Supply Inc. in California. The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations.
Approximately 1,471 bottles are affected by this Class II recall. The affected product was distributed nationwide to patients in Pennsylvania, Massachusetts, Ohio, Texas, Illinois, North Dakota, and Hawaii. Multiple lot numbers are affected, with expiration dates ranging from June 2022 through November 2023. Specific lot information and expiration dates are documented in FDA recall notice D-1177-2022.
No illnesses or injuries have been reported in connection with this recall. Golden State Medical Supply Inc. voluntarily initiated the recall on March 16, 2022.
Patients or healthcare providers who have this medication should contact their pharmacy to determine if they have affected product. Patients should not discontinue their medication without consulting their healthcare provider. Healthcare providers can advise on appropriate next steps, including whether an alternative medication is needed.
The recalled product
- Product
- ENALAPRIL MALEATE (ENALAPRIL MALEATE)
- Brand
- ENALAPRIL MALEATE
- Manufacturer
- Golden State Medical Supply Inc.
- Category
- Drug — Prescription
- Hazard
- Affected units
- 1,471
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lots: GS028301
- 2.5 mg
- 90 tablets
- Exp.: 06/2022
- Lots: GS029973
- GS029974
- GS031436
- GS031715
- GS033191
- GS033940
- Exp. : 10/2022
- Lot: GS034212
- Exp.: 12/2022
- Lot: GS035315
- GS035945
- GS036905
- GS038038
- GS039199
- Exp.: 04/2023
- Lot: GS039200
Distribution
Part of a larger recall action
This product is one of 4 recalled by Golden State Medical Supply Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same brand · ENALAPRIL MALEATE
- ModerateEnalapril Maleate 20 mg tablets recalled for out-of-specification impurities
FDA (Drugs) · 2026-05-13
- ModerateEnalapril Maleate Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2022-07-13
- ModeratePrescription Drug Recall: Enalapril Maleate Due to Manufacturing Deviations
FDA (Drugs) · 2022-07-13
- ModerateFDA Recalls Enalapril Maleate Tablets Over Manufacturing Practice Deviations
FDA (Drugs) · 2022-07-13
Same manufacturer · Golden State Medical Supply Inc.
See all →- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- HighBaclofen tablet bottles recalled over the presence of foreign tablets
FDA (Drugs) · 2025-12-24
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19